CD8+ T Cells Mediate Robust Stage-Specific Immunity to P. berghei under Chemoprophylaxis and This Protective Environment Is Not Downregulated by the Presence of Blood-Stage Infection
Sterile protection against malaria infection can be achieved by the inoculation of intact sporozoites while treating concomitantly with the 4-aminoquinoline chloroquine. We present an analysis of protective immunity elicited by successive immunization with Plasmodium berghei sporozoites under chemoprophylaxis. Immunization resulted in a protective, stage-specific immune response. Protection appeared to be mediated by CD8+ T cells and was abrogated upon their specific depletion. Adoptive transfer of splenocytes rendered recipient animals resistant to sporozoite infection, but not to blood-stage challenge. Immunization with sporozoites under chemoprophylaxis results in robust immunity, and the presence of blood-stage infection at sporozoite immunization had no downregulating effect on the protective immune response.
References
[1]
Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, et al. (2012) Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379: 413–431. doi: 10.1016/s0140-6736(12)60034-8
[2]
Langhorne J, Ndungu FM, Sponaas AM, Marsh K (2008) Immunity to malaria: more questions than answers. Nat Immunol 9: 725–732. doi: 10.1038/ni.f.205
[3]
Bull PC, Lowe BS, Kortok M, Molyneux CS, Newbold CI, et al. (1998) Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat Med 4: 358–360. doi: 10.1038/nm0398-358
[4]
Hoffman SL, Wistar R Jr, Ballou WR, Hollingdale MR, Wirtz RA, et al. (1986) Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum. N Engl J Med 315: 601–606. doi: 10.1056/nejm198609043151001
[5]
Nussenzweig RS, Vanderberg J, Most H, Orton C (1967) Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature 216: 160–162. doi: 10.1038/216160a0
[6]
Mueller AK, Labaied M, Kappe SH, Matuschewski K (2005) Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433: 164–167. doi: 10.1038/nature03188
[7]
Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, et al. (2009) Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 361: 468–477. doi: 10.1056/nejmoa0805832
[8]
Putrianti ED, Silvie O, Kordes M, Borrmann S, Matuschewski K (2009) Vaccine-like immunity against malaria by repeated causal-prophylactic treatment of liver-stage Plasmodium parasites. J Infect Dis 199: 899–903. doi: 10.1086/597121
[9]
Friesen J, Matuschewski K (2011) Comparative efficacy of pre-erythrocytic whole organism vaccine strategies against the malaria parasite. Vaccine 29: 7002–7008. doi: 10.1016/j.vaccine.2011.07.034
[10]
Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, et al. (2002) Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185: 1155–1164. doi: 10.1086/339409
[11]
Mueller AK, Camargo N, Kaiser K, Andorfer C, Frevert U, et al. (2005) Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc Natl Acad Sci U S A 102: 3022–3027. doi: 10.1073/pnas.0408442102
[12]
van Dijk MR, Douradinha B, Franke-Fayard B, Heussler V, van Dooren MW, et al. (2005) Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc Natl Acad Sci U S A 102: 12194–12199. doi: 10.1073/pnas.0500925102
[13]
Yayon A, Cabantchik ZI, Ginsburg H (1985) Susceptibility of human malaria parasites to chloroquine is pH dependent. Proc Natl Acad Sci U S A 82: 2784–2788. doi: 10.1073/pnas.82.9.2784
[14]
Chou AC, Chevli R, Fitch CD (1980) Ferriprotoporphyrin IX fulfills the criteria for identification as the chloroquine receptor of malaria parasites. Biochemistry 19: 1543–1549. doi: 10.1021/bi00549a600
[15]
Orjih AU, Ryerse JS, Fitch CD (1994) Hemoglobin catabolism and the killing of intraerythrocytic Plasmodium falciparum by chloroquine. Experientia 50: 34–39. doi: 10.1007/bf01992046
[16]
Nganou-Makamdop K, van Gemert GJ, Arens T, Hermsen CC, Sauerwein RW (2012) Long term protection after immunization with P. berghei sporozoites correlates with sustained IFNgamma responses of hepatic CD8+ memory T cells. PLoS One 7: e36508. doi: 10.1371/journal.pone.0036508
[17]
Belnoue E, Costa FT, Frankenberg T, Vigario AM, Voza T, et al. (2004) Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J Immunol 172: 2487–2495. doi: 10.4049/jimmunol.172.4.2487
[18]
Ocana-Morgner C, Mota MM, Rodriguez A (2003) Malaria blood stage suppression of liver stage immunity by dendritic cells. J Exp Med 197: 143–151. doi: 10.1084/jem.20021072
[19]
Orjih AU (1985) Acute malaria prolongs susceptibility of mice to Plasmodium berghei sporozoite infection. Clin Exp Immunol 61: 67–71.
[20]
Yoeli M, Most H (1965) Pre-Erythrocytic Development of Plasmodium Berghei. Nature 205: 715–716. doi: 10.1038/205715a0
[21]
Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J (1982) Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42: 3858–3863.
[22]
Tsuji M, Mattei D, Nussenzweig RS, Eichinger D, Zavala F (1994) Demonstration of heat-shock protein 70 in the sporozoite stage of malaria parasites. Parasitology research 80: 16–21. doi: 10.1007/bf00932618
[23]
Wang Q, Li SH, Wang H, Xiao Y, Sahin O, et al. (2012) Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer research 72: 4417–4428. doi: 10.1158/0008-5472.can-12-1339-t
[24]
Fink E (1974) Assessment of causal prophylactic activity in Plasmodium berghei yoelii and its value for the development of new antimalarial drugs. Bull World Health Organ 50: 213–222.
[25]
Most H, Montuori WA (1975) Rodent systems (Plasmodium berghei-Anopheles Stephensi) for screening compounds for potential causal prophylaxis. Am J Trop Med Hyg 24: 179–182.
[26]
Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, et al. (2006) Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. The American journal of tropical medicine and hygiene. 75: 402–415.
[27]
Beaudoin RL, Strome CP, Mitchell F, Tubergen TA (1977) Plasmodium berghei: immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen. Exp Parasitol 42: 1–5. doi: 10.1016/0014-4894(77)90054-6
[28]
Lewis MD, Pfeil J, Mueller AK (2011) Continuous oral chloroquine as a novel route for Plasmodium prophylaxis and cure in experimental murine models. BMC Res Notes 4: 262. doi: 10.1186/1756-0500-4-262
[29]
Nganou-Makamdop K, Ploemen I, Behet M, Van Gemert GJ, Hermsen C, et al. (2012) Reduced Plasmodium berghei sporozoite liver load associates with low protective efficacy after intradermal immunization. Parasite Immunol 34: 562–569. doi: 10.1111/pim.12000.x
[30]
Mueller AK, Deckert M, Heiss K, Goetz K, Matuschewski K, et al. (2007) Genetically attenuated Plasmodium berghei liver stages persist and elicit sterile protection primarily via CD8 T cells. Am J Pathol 171: 107–115. doi: 10.2353/ajpath.2007.060792
[31]
Bijker EM, Bastiaens GJ, Teirlinck AC, van Gemert GJ, Graumans W, et al. (2013) Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci U S A.
[32]
Orjih AU, Nussenzweig RS (1979) Plasmodium berghei: suppression of antibody response to sporozoite stage by acute blood stage infection. Clin Exp Immunol 38: 1–8.
[33]
Portugal S, Carret C, Recker M, Armitage AE, Goncalves LA, et al. (2011) Host-mediated regulation of superinfection in malaria. Nat Med 17: 732–737. doi: 10.1038/nm.2368
[34]
Menard R, Tavares J, Cockburn I, Markus M, Zavala F, et al. (2013) Looking under the skin: the first steps in malarial infection and immunity. Nat Rev Microbiol 11: 701–712. doi: 10.1038/nrmicro3111
